“I’m Willing To Try Anything”: Compassionate Use Access To Experimental Drugs And The Misguided Mission Of Right-To-Try Laws

Health Affairs Blog, 27 March 2017
Authors: Amy Scharf, Elizabeth Dzeng
“Beneath its seemingly altruistic and uncontroversial veneer, the Compassionate Use program has been a lightning rod for intense legal, legislative, and public policy controversies, many of which have been framed as ‘libertarian vs. regulatory’ battles between those who wish to allow patients freer, even unrestricted, access to experimental drugs (often by changing or limiting the role of the FDA), and those who prefer a more measured, rigorous approach to dispensing unproven and potentially dangerous therapies.”
Find article here.